Kromatid

United States
Longmont, Colorado, United States, 80501

Company profile

Kromatid company profile

KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents. It's molecular cytogenetic and GeneTracker assays discover, detect, and diagnose the range of disease-causing mutations - including inversions and translocations - in a single test. Based on Directional Genomic Hybridization (dGH), KromaTiD's assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies Co-founders Andrew Ray, Joel Bedford, Michael Cornforth, and Susan M. Bailey headquartered the company in Fort Collins, Colorado in 2007.

Business identity

Contact email
[email protected]
Phone number
720-815-2898
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$1M-$10M
Founded
2007-01-01, Year

Headquarters

Postal code
80501
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
8
Total equity funding
$28.1M
Last funding
Series C / $8M / 2025-08-20
Last equity funding
Series C / $8M
Investors
3
Lead investors
3
Founders
4
Articles
34

Founders and investors

Founders

Andrew RayJoel BedfordMichael CornforthSusan M. Bailey

Lead investors

BroadOak Capital PartnersFirst Capital VenturesSmall Business Innovation Research

Investors

BroadOak Capital PartnersFirst Capital VenturesSmall Business Innovation Research